Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €27.59 EUR
Change Today +1.02 / 3.85%
Volume 100.0
As of 11:22 AM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (LDB) Snapshot

Open
€26.88
Previous Close
€26.56
Day High
€27.59
Day Low
€26.88
52 Week High
08/19/15 - €28.03
52 Week Low
10/15/14 - €14.94
Market Cap
5.4B
Average Volume 10 Days
137.5
EPS TTM
--
Shares Outstanding
196.6M
EX-Date
03/26/15
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for H LUNDBECK A/S (LDB)

Related News

No related news articles were found.

h lundbeck a/s (LDB) Details

H. Lundbeck A/S researches, develops, produces, and sells pharmaceuticals for the treatment of brain disorders in Denmark and internationally. The company offers pharmaceutical products for the treatment of schizophrenia, major depressive disorder, symptomatic neurogenic orthostatic hypotension, lennox-gastaut syndrome, and alcohol dependence. It also offers other products for the treatment of Alzheimer’s disease, depression and anxiety, Parkinson’s disease, chorea associated with Huntington’s disease, relapsed indolent B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, manic episodes associated with bipolar 1 disorder, and refractory complex partial seizures. In addition, the company is involved in the development of Brexpiprazole, a novel investigational psychotherapeutic compound; and Idalopirdine, a potent and selective 5-HT6 receptor antagonist that are in Phase III clinical trails. It has strategic alliances with various companies, including Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited. The company was founded in 1915 and is headquartered in Valby, Denmark.

5,801 Employees
Last Reported Date: 08/19/15
Founded in 1915

h lundbeck a/s (LDB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (LDB) Key Developments

H. Lundbeck A/S, Q2 2015 Earnings Call, Aug 19, 2015

H. Lundbeck A/S, Q2 2015 Earnings Call, Aug 19, 2015

H. Lundbeck A/S Reports Earnings Results for the Second Quarter of 2015

H. Lundbeck A/S reported earnings results for the second quarter of 2015. For the quarter, the company reported a DKK 4.8 billion in reported LBIT. Operating cash flow has been impacted by the payment to Otsuka in the spring of $200 million, and the company have a net debt of DKK 1.4 billion by the end of the quarter.

H. Lundbeck A/S Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revised Earnings Guidance for the Full Year 2015; Provides Impairment Guidance for the Third Quarter of 2015

H. Lundbeck A/S announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of DKK 3,629 million against DKK 3,448 million a year ago. LBITDA was DKK 4,548 million against EBITDA of DKK 540 million a year ago. Loss from operations was DKK 4,833 million against profit from operations of DKK 274 million a year ago. Loss before tax was DKK 4,900 million against profit before tax of DKK 144 million a year ago. Loss for the period was DKK 3,906 million or DKK 19.86 per diluted share against profit of DKK 144 million or DKK 0.73 per diluted share a year ago. Cash flows used in operating activities were DKK 1,384 million against cash flows from operating activities of DKK 459 million a year ago. Negative return on equity was 31.9% against return on equity of 1.1% a year ago. Core profit from operations (core EBIT) was DKK 135 million against DKK 439 million a year ago. Negative cash flow per share was DKK 7.04 against cash flow per share of DKK 2.33 a year ago. The performance in revenue was caused by the generic competition of Cipralex in Canada where sales declined by 81% to DKK 51 million which was compensated for by growth in other products and geographies including emerging markets. The decrease in EBITDA margin is related to the reclassification of product rights and generic impact on the revenue from Cipralex as well as launch and pre-launch activities. For the six months, the company reported revenue of DKK 7,192 million against DKK 7,035 million a year ago. LBITDA was DKK 4,240 million against EBITDA of DKK 1,364 million a year ago. Loss from operations was DKK 4,865 million against profit from operations of DKK 843 million a year ago. Loss before tax was DKK 4,932 million against profit before tax of DKK 792 million a year ago. Loss for the period was DKK 3,987 million against profit of DKK 475 million a year ago. Diluted loss per share were DKK 20.28 against DKK 2.42 diluted earnings per share a year ago. Cash flows used in operating activities were DKK 1,766 million against cash flows from operating activities of DKK 308 million a year ago. Investments in intangible assets and property, plant and equipment was DKK 35 million against DKK 1,277 million a year ago. Negative return on equity was 33.6% against return on equity of 3.5% a year ago. Negative cash flow per share was DKK 8.99 against cash flow per share of DKK 1.57 a year ago. Core profit from operations (core EBIT) was DKK 351 million against DKK 1,168 million a year ago. The increase in revenue of 2% is caused by a positive development in main currencies. For 2015, the company expects core revenue of DKK 14 billion against previous forecast of DKK 13.2 to 13.7 billion and core EBIT of DKK 0.5 billion and reported LBIT of DKK 7 billion. For the third quarter, the company expects to recognize approximately DKK 0.6 billion in impairment loss due to changed management estimates of certain intangible rights and fixed assets.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LDB:GR €27.59 EUR +1.02

LDB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ipsen SA €59.55 EUR +3.49
Lupin Ltd 1,900 INR +89.45
Meda AB kr128.10 SEK +2.10
Orion Oyj €35.36 EUR +0.33
Recordati SpA €21.44 EUR +0.24
View Industry Companies
 

Industry Analysis

LDB

Industry Average

Valuation LDB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit www.lundbeck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.